A new treatment option for advanced cervical cancer that has stopped responding to immunotherapy
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have cervical cancer that has come back or spread to other parts of the body.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score of 0 or 1).
- Your cancer has gotten worse after at least one prior treatment with an immunotherapy drug (like PD-1 or PD-L1 inhibitors).
- Your blood counts, liver, and kidney function are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) for cervical cancer that has stopped responding to earlier PD-1 therapies. The goal is to see if this drug can help shrink tumors or slow down the cancer.
This study tests a new drug combination for people with advanced cervical cancer that has spread or returned after platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a new immunotherapy drug (QL1706) combined with hormone therapy for breast cancer that is hormone receptor positive and HER2 negative, but did not respond well to initial chemotherapy. The goal is to see if this combination can shrink tumors before surgery and potentially improve outcomes.
Hear when a new Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.